ArticleBMC gastroenterology2026
Association of the C-reactive protein-triglyceride-glucose index with liver disease risk: findings from a nationwide Chinese cohort.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study.Cardiovascular diabetology · 2026Article
- C-reactive protein-triglyceride-glucose index (CTI) as a predictor of chronic liver disease in adults with macrocytic anemia.Scientific reports · 2026Article
- The association of the combined triglyceride-glucose and frailty index with chronic liver disease: evidence from the CHARLS study.BMC gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBoth insulin resistance and low-grade inflammation contribute to liver disease development, yet their combined predictive role remains unclear at the population level.
methodsIn this prospective nationwide cohort study, we analyzed 9,302 participants aged ≥ 45 years from the China Health and Retirement Longitudinal Study who were free of liver disease at baseline. Additionally, CTI was calculated as 0.412 × ln (C-reactive protein [CRP, mg/L]) + ln((triglycerides [TG, mg/dL] × fasting plasma glucose [FPG, mg/dL])/2). Incident self-reported, physician-diagnosed liver disease was identified during follow-up interviews. Associations between CTI and liver disease were assessed using Cox regression, Kaplan–Meier survival curves, and restricted cubic splines analyses. Subgroup and mediation analyses were conducted for low-density and high-density lipoprotein cholesterol.
resultsOver 81,229 person-years of follow-up, higher CTI was independently associated with an increased risk of incident self-reported, physician-diagnosed liver disease, with risk increasing progressively across CTI quartiles. This positive association was consistent in men and women, with approximately linear dose–response relationships in both sexes and no meaningful sex differences. Mediation through low- and high-density lipoprotein cholesterol was negligible. Findings remain robust in multiple sensitivity analyses, including exclusion of participants who reported high-risk alcohol consumption.
conclusionElevated CTI is a simple, low-cost biomarker that may help identify individuals at increased risk of liver disease, particularly in settings where comprehensive liver function panels are unavailable. Rather than replacing guideline-recommended fibrosis scores, CTI may serve as a complementary early risk indicator to support population-level risk stratification and inform targeted prevention and follow-up efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.